Disposition of metformin on concomitant administration of erlotinib and meloxicam in SCID mice
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker, Shailesh K Bhavsar and Harilal Patel
Pharmacokinetics of metformin was evaluated following its single dose administration alone and administered with erlotinib and/or meloxicam in SCID mice. Following administration of metformin as a single drug in male SCID mice, the mean values of observed peak plasma drug concentration (Cmax), time of maximum concentration (Tmax), area under plasma drug concentration-time curve (AUC0-¥), volume of distribution (Vz), elimination half-life (t½β) and total body clearance (Cl) were 6277.75 ± 404.25 ng/ml, 0.61 ± 0.10 h, 17218.83 ± 885.71 ng.h/ml, 28950.33 ± 3629.19 ml, 3.36 ± 0.27 h and 5897.32 ± 350.95 ml/h, respectively. Erlotinib and/or meloxicam administration was found to alter pharmacokinetic profile of metformin in SCID mice. Thus, close therapeutic monitoring should be followed for long term concomitant administration of these drugs. However, study on clinical pharmacokinetic interaction of these drugs is required to evaluate interaction in human patients.
How to cite this article:
Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker, Shailesh K Bhavsar, Harilal Patel. Disposition of metformin on concomitant administration of erlotinib and meloxicam in SCID mice. Pharma Innovation 2018;7(3):173-177.